ZURICH, March 19 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday ...

Swiss drugmakers Novartis and Roche ditch some diversity programmes on US concerns Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of ...

Novartis agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company ...

The finance sector is strongly represented in this year's attendees. HSBC Group Chief Executive Georges Elhedery is on the ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...

Novartis is paying Kyorin $55 million upfront to develop, manufacture and commercialize a preclinical mast-cell-targeting candidate for chronic hives.